Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-cash Items: 2012-2025

Historic Non-cash Items for Enanta Pharmaceuticals (ENTA) over the last 12 years, with Sep 2025 value amounting to $6.5 million.

  • Enanta Pharmaceuticals' Non-cash Items rose 356.00% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 356.00%. This contributed to the annual value of $6.5 million for FY2025, which is 85.44% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Non-cash Items is $6.5 million, which was up 66.72% from $3.9 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Non-cash Items high stood at $97.2 million for Q4 2021, and its period low was $2,000 during Q2 2023.
  • For the 3-year period, Enanta Pharmaceuticals' Non-cash Items averaged around $2.8 million, with its median value being $3.0 million (2023).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Non-cash Items plummeted by 99.92% in 2023, and later skyrocketed by 209,350.00% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Non-cash Items stood at $97.2 million in 2021, then crashed by 81.84% to $17.6 million in 2022, then plummeted by 97.40% to $459,000 in 2023, then surged by 209,350.00% to $1.4 million in 2024, then skyrocketed by 356.00% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, $3.9 million for Q2 2025, and $1.4 million during Q3 2024.